Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12748474 | 0.84 | HTT (0.36) | HTTKCNE1KCNQ1ABCB1MAOA | |
| SCHEMBL12748471 | 0.84 | HTT (0.36) | HTTKCNE1KCNQ1ABCB1MAOA | |
| SCHEMBL12748473 | 0.84 | HTT (0.36) | HTTKCNE1KCNQ1ABCB1MAOA | |
| SCHEMBL31253977 | 0.81 | MEN1 (0.43) | HTTKCNE1KCNQ1MAOAMAOB | |
| SCHEMBL3580439 | 0.81 | MEN1 (0.43) | HTTKCNE1KCNQ1MAOAMAOB | |
| SCHEMBL13573386 | 0.81 | MEN1 (0.43) | HTTKCNE1KCNQ1MAOAMAOB | |
| SCHEMBL15021653 | 0.81 | MEN1 (0.43) | HTTKCNE1KCNQ1MAOAMAOB | |
| SCHEMBL5733934 | 0.78 | KCNE1 (0.38) | HTTKCNE1KCNQ1MAOAMAOB | |
| SCHEMBL24043241 | 0.78 | SCD (0.35) | HTTABCB1MAPK1LMNAOPRD1 | |
| Alcohol SCHEMBL10531474 | 0.75 | KCNE1 (0.42) | HTTKCNE1KCNQ1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2483/4885KCNE1 4728/4885KCNQ1 4615/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2483/4885KCNE1 4728/4885KCNQ1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.